Role of epidermal growth factor receptor in acute and chronic kidney injury

Kidney International

Volumn 83, Issue 5, 2013, Pages 804-810

  Tang, Jinhua ^a,b   Liu, Na ^a,b   Zhuang, Shougang ^a,b  

^a BROWN UNIVERSITY   (United States)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

acute renal injury; chronic kidney diseases; clinical relevance; EGFR; signaling pathway

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; TRANSFORMING GROWTH FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ALBUMINURIA; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; HUMAN; HYPERTENSION; HYPERTENSIVE NEPHROPATHY; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY ISCHEMIA; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; TRANSACTIVATION; URINE VOLUME;

EID: 84877015143     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.435     Document Type: Review

References (89)

1. Melenhorst WB, Mulder GM, Xi Q et al. Epidermal growth factor receptor signaling in the kidney: key roles in physiology and disease. Hypertension 2008; 52: 987-993.
2. Zeng F, Singh AB, Harris RC. The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology. Exp Cell Res 2009; 315: 602-610.
3. Huovila AP, Turner AJ, Pelto-Huikko M et al. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 2005; 30: 413-422.
4. Lautrette A, Li S, Alili R et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005; 11: 867-874.
5. Asakura M, Kitakaze M, Takashima S et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002; 8: 35-40.
6. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002; 110: 669-672.
7. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
8. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
9. Li Y, Levesque LO, Anand-Srivastava MB. Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am J Physiol Heart Circ Physiol 2010; 299: H1959-H1967.
10. Feigin ME, Muthuswamy SK. ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. Exp Cell Res 2009; 315: 707-716.
11. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
12. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
13. Kobayashi M, Iwamatsu A, Shinohara-Kanda A et al. Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. Oncogene 2003; 22: 1294-1301.
14. Minner S, Rump D, Tennstedt P et al. Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer 2011; 118: 1268-1275.
15. Patereli A, Alexiou GA, Stefanaki K et al. Expression of epidermal growth factor receptor and HER-2 in pediatric embryonal brain tumors. Pediatr Neurosurg 2010; 46: 188-192.
16. Rego RL, Foster NR, Smyrk TC et al. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 2010; 102: 165-172.
17. Luo G, Long J, Qiu L et al. Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: a meta-analysis. Pancreatology 2011; 11: 595-600.
18. Naik DS, Sharma S, Ray A et al. Epidermal growth factor receptor expression in urinary bladder cancer. Indian J Urol 2011; 27: 208-214.
19. Goodyer PR, Cybulsky A, Goodyer C. Expression of the epidermal growth factor receptor in fetal kidney. Pediatr Nephrol 1993; 7: 612-615.
20. Advani A, Wiggins KJ, Cox AJ et al. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology (Carlton) 2011; 16: 573-581.
21. Wen X, Murugan R, Peng Z et al. Pathophysiology of acute kidney injury: a new perspective. Contrib Nephrol 2010; 165: 39-45.
22. Chen J, Chen JK, Harris RC. Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury. Kidney Int 2012; 82: 45-52.
23. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
24. Bonventre JV. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003; 14: S55-S61.
25. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962; 237: 1555-1562.
26. Carev D, Saraga M, Saraga-Babic M. Expression of intermediate filaments, EGF and TGF-alpha in early human kidney development. J Mol Histol 2008; 39: 227-235.
27. Takemura T, Hino S, Okada M et al. Role of membrane-bound heparinbinding epidermal growth factor-like growth factor (HB-EGF) in renal epithelial cell branching. Kidney Int 2002; 61: 1968-1979.
28. Threadgill DW, Dlugosz AA, Hansen LA et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995; 269: 230-234.
29. Hise MK, Salmanullah M, Liu L et al. Control of the epidermal growth factor receptor and its ligands during renal injury. Nephron 2001; 88: 71-79.
30. Homma T, Sakai M, Cheng HF et al. Induction of heparin-binding epidermal growth factor-like growth factor mRNA in rat kidney after acute injury. J Clin Invest 1995; 96: 1018-1025.
31. Sakai M, Zhang M, Homma T et al. Production of heparin binding epidermal growth factor-like growth factor in the early phase of regeneration after acute renal injury. Isolation and localization of bioactive molecules. J Clin Invest 1997; 99: 2128-2138.
32. Wang Z, Chen JK, Wang SW et al. Importance of functional EGF receptors in recovery from acute nephrotoxic injury. J Am Soc Nephrol 2003; 14: 3147-3154.
33. Humes HD, Cieslinski DA, Coimbra TM et al. Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure. J Clin Invest 1989; 84: 1757-1761.
34. Norman J, Tsau YK, Bacay A et al. Epidermal growth factor accelerates functional recovery from ischaemic acute tubular necrosis in the rat: role of the epidermal growth factor receptor. Clin Sci (Lond) 1990; 78: 445-450.
35. Humphreys BD, Valerius MT, Kobayashi A et al. Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell 2008; 2: 284-291.
36. Zhuang S, Yan Y, Han J et al. p38 kinase-mediated transactivation of the epidermal growth factor receptor is required for dedifferentiation of renal epithelial cells after oxidant injury. J Biol Chem 2005; 280: 21036-21042.
37. Zhuang S, Dang Y, Schnellmann RG. Requirement of the epidermal growth factor receptor in renal epithelial cell proliferation and migration. Am J Physiol Renal Physiol 2004; 287: F365-F372.
38. Zhuang S, Yan Y, Daubert RA et al. Epiregulin promotes proliferation and migration of renal proximal tubular cells. Am J Physiol Renal Physiol 2007; 293: F219-F226.
39. Humphreys BD, Czerniak S, DiRocco DP et al. Repair of injured proximal tubule does not involve specialized progenitors. Proc Natl Acad Sci USA 2011; 108: 9226-9231.
40. Yang L, Besschetnova TY, Brooks CR et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-543(531p following 143).
41. Terzi F, Burtin M, Hekmati M et al. Targeted expression of a dominantnegative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J Clin Invest 2000; 106: 225-234.
42. Chen J, Chen JK, Nagai K et al. EGFR signaling promotes TGFbetadependent renal fibrosis. J Am Soc Nephrol 2012; 23: 215-224.
43. Liu N, Guo JK, Pang M et al. Genetic or pharmacologic blockade of EGFR Inhibits renal fibrosis. J Am Soc Nephrol 2012; 23: 854-867.
44. Francois H, Placier S, Flamant M et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. Faseb J 2004; 18: 926-928.
45. Laouari D, Burtin M, Phelep A et al. TGF-alpha mediates genetic susceptibility to chronic kidney disease. J Am Soc Nephrol 2011; 22: 327-335.
46. Laouari D, Burtin M, Phelep A et al. A transcriptional network underlies susceptibility to kidney disease progression. EMBO Mol Med 2012; 4: 825-839.
47. Wassef L, Kelly DJ, Gilbert RE. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int 2004; 66: 1805-1814.
48. Mogensen CE, Andersen MJ. Increased kidney size and glomerular filtration rate in early juvenile diabetes. Diabetes 1973; 22: 706-712.
49. Seyer-Hansen K. Renal hypertrophy in experimental diabetes mellitus. Kidney Int 1983; 23: 643-646.
50. Kleinman KS, Fine LG. Prognostic implications of renal hypertrophy in diabetes mellitus. Diabetes Metab Rev 1988; 4: 179-189.
51. Inomata S. Renal hypertrophy as a prognostic index for the progression of diabetic renal disease in non-insulin-dependent diabetes mellitus. J Diabetes Complications 1993; 7: 28-33.
52. Panchapakesan U, Pollock C, Saad S. Renal epidermal growth factor receptor: its role in sodium and water homeostasis in diabetic nephropathy. Clin Exp Pharmacol Physiol 2011; 38: 84-88.
53. Gilbert RE, Huang Q, Thai K et al. Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int 2011; 79: 1312-1321.
54. Konishi A, Berk BC. Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells. J Biol Chem 2003; 278: 35049-35056.
55. Gilbert RE, Cox A, McNally PG et al. Increased epidermal growth factor in experimental diabetes related kidney growth in rats. Diabetologia 1997; 40: 778-785.
56. Lee YJ, Shin SJ, Lin SR et al. Increased expression of heparin binding epidermal growth-factor-like growth factor mRNA in the kidney of streptozotocin-induced diabetic rats. Biochem Biophys Res Commun 1995; 207: 216-222.
57. Wu D, Peng F, Zhang B et al. PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells. J Am Soc Nephrol 2009; 20: 554-566.
58. Wu D, Peng F, Zhang B et al. Collagen I induction by high glucose levels is mediated by epidermal growth factor receptor and phosphoinositide 3-kinase/Akt signalling in mesangial cells. Diabetologia 2007; 50: 2008-2018.
59. Benter IF, Canatan H, Benboubetra M et al. Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: a microarray analysis. Vascul Pharmacol 2009; 51: 101-109.
60. Ying WZ, Sanders PW. Enhanced expression of EGF receptor in a model of salt-sensitive hypertension. Am J Physiol Renal Physiol 2005; 289: F314-F321.
61. Swaminathan N, Vincent M, Sassard J et al. Elevated epidermal growth factor receptor levels in hypertensive Lyon rat kidney and aorta. Clin Exp Pharmacol Physiol 1996; 23: 793-796.
62. Carmines PK, Fallet RW, Che Q et al. Tyrosine kinase involvement in renal arteriolar constrictor responses to angiotensin II. Hypertension 2001; 37: 569-573.
63. Flamant M, Tharaux PL, Placier S et al. Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 2003; 17: 327-329.
64. Che Q, Carmines PK. Angiotensin II triggers EGFR tyrosine kinasedependent Ca2\+ influx in afferent arterioles. Hypertension 2002; 40: 700-706.
65. Ushio-Fukai M, Griendling KK, Becker PL et al. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21: 489-495.
66. Eguchi S, Numaguchi K, Iwasaki H et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin IIinduced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 1998; 273: 8890-8896.
67. Ryan S, Verghese S, Cianciola NL et al. Autosomal recessive polycystic kidney disease epithelial cell model reveals multiple basolateral epidermal growth factor receptor sorting pathways. Mol Biol Cell 2010; 21: 2732-2745.
68. Sack E, Talor Z. High affinity binding sites for epidermal growth factor (EGF) in renal membranes. Biochem Biophys Res Commun 1988; 154: 312-317.
69. Goodyer PR, Kachra Z, Bell C et al. Renal tubular cells are potential targets for epidermal growth factor. Am J Physiol 1988; 255: F1191-F1196.
70. Sweeney WE, Chen Y, Nakanishi K et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 2000; 57: 33-40.
71. Du J, Wilson PD. Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am J Physiol 1995; 269: C487-C495.
72. Richards WG, Sweeney WE, Yoder BK et al. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Invest 1998; 101: 935-939.
73. Nakanishi K, Gattone VH 2nd, Sweeney WE et al. Renal dysfunction but not cystic change is ameliorated by neonatal epidermal growth factor in bpk mice. Pediatr Nephrol 2001; 16: 45-50.
74. Lee DC, Chan KW, Chan SY. Expression of transforming growth factor alpha and epidermal growth factor receptor in adult polycystic kidney disease. J Urol 1998; 159: 291-296.
75. MacRae Dell K, Nemo R, Sweeney WE Jr et al. EGF-related growth factors in the pathogenesis of murine ARPKD. Kidney Int 2004; 65: 2018-2029.
76. Bollee G, Flamant M, Schordan S et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 2011; 17: 1242-1250.
77. Harris R. EGFR signaling in podocytes at the root of glomerular disease. Nat Med 2011; 17: 1188-1189.
78. Paizis K, Kirkland G, Khong T et al. Heparin-binding epidermal growth factor-like growth factor is expressed in the adhesive lesions of experimental focal glomerular sclerosis. Kidney Int 1999; 55: 2310-2321.
79. Paizis K, Kirkland G, Polihronis M et al. Heparin-binding epidermal growth factor-like growth factor in experimental models of membranous and minimal change nephropathy. Kidney Int 1998; 53: 1162-1171.
80. Sis B, Sarioglu S, Celik A et al. Epidermal growth factor receptor expression in human renal allograft biopsies: an immunohistochemical study. Transpl Immunol 2004; 13: 229-232.
81. Pape L, Henne T, Offner G et al. Computer-assisted quantification of fibrosis in chronic allograft nephropaty by picosirius red-staining: a new tool for predicting long-term graft function. Transplantation 2003; 76: 955-958.
82. Michailova KN, Usunoff KG. Serosal membranes (pleura, pericardium, peritoneum). Normal structure, development and experimental pathology. Adv Anat Embryol Cell Biol 2006; 183, i-vii, 1-144, back cover.
83. Faull RJ, Stanley JM, Fraser S et al. HB-EGF is produced in the peritoneal cavity and enhances mesothelial cell adhesion and migration. Kidney Int 2001; 59: 614-624.
84. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12: 14-27.
85. Leavesley DI, Stanley JM, Faull RJ. Epidermal growth factor modifies the expression and function of extracellular matrix adhesion receptors expressed by peritoneal mesothelial cells from patients on CAPD. Nephrol Dial Transplant 1999; 14: 1208-1216.
86. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315: 971-979.
87. Rosell R, Robinet G, Szczesna A et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008; 19: 362-369.
88. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res 2006; 12: 4377s-4383s.
89. Cappuzzo F, Bemis L, Varella-Garcia M. Her2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006; 354: 2619-2621.